Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2016 Publisher: Martindale Pharmaceuticals Ltd, Bampton Road, Harold Hill, Romford, RM3 8UG
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
The product should not be used in patients with closed angle glaucoma.
It is also contraindicated in patients with narrow angle between the iris and the cornea since it may raise intra-ocular pressure and precipitate an acute attack of closed angle glaucoma.
It should not be used by patients with known hypersensitivity to any component of the preparation.
It should only be used with caution in patients who may have raised intra ocular pressure.
The product contains benzalkonium chloride solution and soft contact lenses must not be worn during the period of use.
Patients should be warned that antimuscarinic eye drops will temporarily impair vision.
Patients should wash hands after using the eye drops and great care should be taken to avoid getting the product into the mouth.
Due to the risk of provoking hyperpyrexia, atropine should only be used with great caution when the ambient temperature is high or the patient has a fever.
Care is also required in patients with conditions characterised by tachycardia.
Darkly pigmented iris is more resistant to pupillary dilation and caution should be exercised to avoid overdosage.
The eye drops should be discarded 4 weeks after first opening.
During use, care should be taken not to touch the dropper nozzle on to the eyelid or any other surface.
The product is for external use only and should be stored out of the sight and reach of children.
The effects of atropine may be enhanced by the concomitant use of other drugs with antimuscarinic properties. Studies have indicated that the absorption of atropine sulphate appears to be delayed by solutions of higher osmolarity.
The safety for use in pregnancy and lactation has not been established, therefore, use only when directed by a physician.
May cause transient blurring of vision on instillation. Warn patients not to drive or operate hazardous machinery until vision is clear.
Patients may experience photophobia and eyes should be protected from bright light while the pupils are dilated.
Prolonged use of atropine eye drops may lead to local irritation, transient stinging, hyperaemia, oedema and conjunctivitis. An increase in intra-ocular pressure may occur, especially in patients with closed angle glaucoma.
Hypersensitivity to atropine is not uncommon and may appear as a skin rash or conjunctivitis.
Systemic toxicity may be produced by the instillation of the eye drops especially in infants and the elderly. Reported symptoms include severe ataxia, restlessness, excitement and hallucinations.
Other adverse effects may include a dry mouth with difficulty in swallowing and talking, flushing and a dry skin, transient bradycardia followed by tachycardia, palpitations and arrhythmias, reduced bronchial secretions, urinary urgency and retention and constipation.
Side effects that occur occasionally include confusion (particularly in the elderly), nausea, vomiting and giddiness.
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
None known relevant to topical ocular use.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
